Compare RLGT & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLGT | OCGN |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.6M | 419.8M |
| IPO Year | 2006 | 2014 |
| Metric | RLGT | OCGN |
|---|---|---|
| Price | $9.22 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.00 | ★ $9.75 |
| AVG Volume (30 Days) | 128.7K | ★ 4.9M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | 31.58 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $902,696,000.00 | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $5.18 | $1,718.38 |
| P/E Ratio | $39.57 | ★ N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $5.78 | $0.90 |
| 52 Week High | $9.45 | $2.73 |
| Indicator | RLGT | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.52 | 35.31 |
| Support Level | $5.86 | $1.09 |
| Resistance Level | N/A | $1.92 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 80.53 | 19.15 |
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").